![[First Release] KATI Medical completed the A+ round of financing of over 70 million ¥, and accelerated the IND application and pipeline development of leading products](/Template/Default/images/none_2x1.jpg)
2022, Nanjing KATI Medical Technology Co., Ltd. (hereinafter referred to as Nanjing KATI), a new domestic solid tumor CAR-T cell therapy company, completed a total of more than 70 million ¥ in A+ round of financing
Nanjing Kati Medical Technology Co., Ltd. won the first prize of the 2020 "Win in Nanjing Entrepreneurship Jinling" Technology Innovation and Entrepreneurship Competition
"Technology leads a healthy future"2020 Nanjing International Life and Health Technology ExpoFinished perfectly!Katy Medical has successfully concluded!
Good news! Nanjing Kati Medicine successfully passed the national high-tech enterprise certification
Good news! Katy won the "Second Prize" in the "Entrepreneurship Jiangsu" competition